Translate Bio, Inc. Sustainability Profile
Translate Bio, Inc., a pioneering biotechnology firm based in the United States, focuses on the development of mRNA therapeutics. Founded in 2016, the company has rapidly advanced its position within the biopharmaceutical industry, particularly in the areas of genetic medicine and vaccine development. With its headquarters in Lexington, Massachusetts, Translate Bio has made significant strides in harnessing the potential of messenger RNA to create innovative treatments for various diseases. The company's core offerings include mRNA-based therapeutics designed to address unmet medical needs, setting it apart through its unique approach to drug development. Recognised for its contributions to the field, Translate Bio has established itself as a key player in the biotechnology landscape, particularly in the context of rapid advancements in mRNA technology.
DitchCarbon Score
How does Translate Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Translate Bio, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Translate Bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Sanofi, and as such, it inherits emissions data and climate commitments from its parent organisation. Translate Bio, Inc. is aligned with Sanofi's climate initiatives, which include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all at a cascade level of 1. However, specific reduction targets or achievements for Translate Bio, Inc. have not been disclosed. As part of its commitment to sustainability, Translate Bio, Inc. is expected to adhere to the broader climate strategies set forth by Sanofi, which may include significant reduction targets and initiatives aimed at minimising carbon emissions across various scopes. However, without specific data or targets available, the details of these commitments remain vague.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Translate Bio, Inc.'s Industry?
How Carbon Intensive is Translate Bio, Inc.'s Location?
Translate Bio, Inc.'s Scope 3 Categories Breakdown
Translate Bio, Inc.'s Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Translate Bio, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Translate Bio, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
